1. Home
  2. TTSH vs SGMT Comparison

TTSH vs SGMT Comparison

Compare TTSH & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tile Shop Holdings Inc.

TTSH

Tile Shop Holdings Inc.

HOLD

Current Price

$6.57

Market Cap

279.3M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.25

Market Cap

238.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTSH
SGMT
Founded
1985
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
279.3M
238.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
TTSH
SGMT
Price
$6.57
$6.25
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.71
AVG Volume (30 Days)
301.2K
508.9K
Earning Date
11-04-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$338,787,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.62
$1.73
52 Week High
$7.75
$11.41

Technical Indicators

Market Signals
Indicator
TTSH
SGMT
Relative Strength Index (RSI) 60.27 39.34
Support Level $6.35 $5.95
Resistance Level $6.57 $6.58
Average True Range (ATR) 0.07 0.36
MACD 0.00 -0.03
Stochastic Oscillator 94.00 24.34

Price Performance

Historical Comparison
TTSH
SGMT

About TTSH Tile Shop Holdings Inc.

Tile Shop Holdings Inc is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It manufactures its setting and maintenance materials, such as thinset, grout, and sealers. The company's primary market is retail sales to consumers, contractors, designers and home builders. Natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. Man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: